Physician profile
Loreta Pytka
NPI 1437673480
$8,715.40
in general payments reported to CMS, 2019-2025
40 companies · $2,449 in 2025
The $2,449 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,190 · 2022: $1,481 · 2023: $825 · 2024: $1,771 · 2025: $2,449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,280 · Travel and Lodging: $765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,280.13 |
| Travel and Lodging | $764.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,603.84 | 2022-2025 | Wavewriter Alpha Prime 16, General - Therapies, General - Dbs |
| Biohaven Pharmaceuticals, INC. | $1,504.61 | 2021 | |
| Abbott Laboratories | $593.24 | 2021-2022 | |
| Collegium Pharmaceutical, INC. | $592.20 | 2021-2025 | Xtampza |
| Pfizer INC. | $516.44 | 2023-2025 | |
| Ibsa Pharma INC. | $343.69 | 2021-2025 | Tirosint, Licart, Flector |
| Abbvie INC. | $269.36 | 2021-2025 | |
| Foundation Fusion Solutions, LLC | $265.47 | 2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $252.00 | 2022 | |
| Medtronic, INC. | $244.99 | 2022-2025 | Venaseal |
| Antares Pharma, INC. | $186.90 | 2024-2025 | Xyosted |
| Janssen Pharmaceuticals, INC | $162.35 | 2024 | Spravato |
| Stimwave Technologies Incorporated | $133.88 | 2022 | |
| Almatica Pharma LLC | $119.45 | 2021-2024 | Gralise, Teriparatide |
| Nevro Corp. | $90.52 | 2022 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endo Pharmaceuticals INC. | $86.68 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $86.14 | 2024-2025 | |
| Forte Bio-Pharma LLC | $73.96 | 2023-2024 | Prolate, Nalocet |
| Azurity Pharmaceuticals, INC. | $62.26 | 2023-2024 | Horizant, Horizant |
| Lilly USA, LLC | $51.38 | 2022-2023 | Emgality |
| Tolmar, INC. | $51.10 | 2024-2025 | Jatenzo |
| Currax Pharmaceuticals LLC | $45.34 | 2023-2024 | Contrave, Onzetra Xsail |
| Exact Sciences Corporation | $31.74 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Uswm, LLC | $31.64 | 2021 | |
| Radius Health, INC. | $30.10 | 2022 | |
| Horizon Therapeutics Plc | $27.12 | 2021 | |
| Idorsia Pharmaceuticals US INC | $24.22 | 2025 | Quviviq |
| Dexcom, INC. | $24.13 | 2025 | Dexcom G6 Transmitter |
| Vertex Pharmaceuticals Incorporated | $23.98 | 2025 | |
| Innovation Technologies INC | $23.82 | 2023 | Irrisept |
| Valinor Pharma, LLC | $20.88 | 2025 | Movantik |
| Takeda Pharmaceuticals U.S.A., INC. | $19.94 | 2021 | |
| Fidia Pharma USA INC. | $18.09 | 2024 | Hyalgan, Hymovis, Triluron |
| Astellas Pharma US INC | $16.93 | 2024 | Veozah |
| Scilex Pharmaceuticals INC. | $16.77 | 2021 | |
| Arbor Pharmaceuticals, INC. | $16.69 | 2021 | |
| Merck Sharp & Dohme LLC | $16.24 | 2021 | |
| Spinal Simplicity, LLC | $15.52 | 2023 | Ha Minuteman G3-R |
| Biodelivery Sciences International, INC. | $12.10 | 2021 | |
| Genentech USA, INC. | $9.69 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Loreta Pytka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.